Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of “Moderate Buy” by Analysts

Celcuity, Inc. (NASDAQ:CELC) has received a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $155.1818.

A number of equities research analysts have issued reports on the company. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. HC Wainwright upped their price objective on Celcuity from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Needham & Company LLC reiterated a “buy” rating and set a $157.00 target price on shares of Celcuity in a research report on Friday, May 15th. Finally, Macquarie Infrastructure set a $160.00 target price on Celcuity in a research note on Thursday, May 28th.

Celcuity Stock Performance

Shares of NASDAQ CELC opened at $92.08 on Thursday. The stock has a market cap of $4.49 billion, a PE ratio of -23.61 and a beta of 0.20. Celcuity has a 1 year low of $44.42 and a 1 year high of $151.02. The firm has a fifty day moving average price of $93.93 and a 200-day moving average price of $108.73. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31.

Celcuity (NASDAQ:CELC) last released its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. Equities analysts anticipate that Celcuity will post -3.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celcuity

A number of institutional investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC purchased a new position in shares of Celcuity in the fourth quarter worth $1,058,000. California State Teachers Retirement System grew its stake in Celcuity by 91.2% during the first quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock valued at $2,920,000 after acquiring an additional 12,201 shares in the last quarter. Jennison Associates LLC purchased a new position in Celcuity during the fourth quarter valued at $22,911,000. Geode Capital Management LLC increased its holdings in Celcuity by 8.4% in the 4th quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock valued at $82,872,000 after acquiring an additional 64,213 shares during the last quarter. Finally, TD Asset Management Inc increased its holdings in Celcuity by 34.0% in the 4th quarter. TD Asset Management Inc now owns 97,526 shares of the company’s stock valued at $9,727,000 after acquiring an additional 24,730 shares during the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.